The New England journal of medicine, 2021-03, Vol.384 (9), p.829-841
- Choueiri, Toni K
- Powles, Thomas
- Burotto, Mauricio
- Escudier, Bernard
- Bourlon, Maria T
- Zurawski, Bogdan
- Oyervides Juárez, Victor M
- Hsieh, James J
- Basso, Umberto
- Shah, Amishi Y
- Suárez, Cristina
- Hamzaj, Alketa
- Goh, Jeffrey C
- Barrios, Carlos
- Richardet, Martin
- Porta, Camillo
- Kowalyszyn, Rubén
- Feregrino, Juan P
- Żołnierek, Jakub
- Pook, David
- Kessler, Elizabeth R
- Tomita, Yoshihiko
- Mizuno, Ryuichi
- Bedke, Jens
- Zhang, Joshua
- Maurer, Matthew A
- Simsek, Burcin
- Ejzykowicz, Flavia
- Schwab, Gisela M
- Apolo, Andrea B
- Motzer, Robert J
2021
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Choueiri, Toni K
- Powles, Thomas
- Burotto, Mauricio
- Escudier, Bernard
- Bourlon, Maria T
- Zurawski, Bogdan
- Oyervides Juárez, Victor M
- Hsieh, James J
- Basso, Umberto
- Shah, Amishi Y
- Suárez, Cristina
- Hamzaj, Alketa
- Goh, Jeffrey C
- Barrios, Carlos
- Richardet, Martin
- Porta, Camillo
- Kowalyszyn, Rubén
- Feregrino, Juan P
- Żołnierek, Jakub
- Pook, David
- Kessler, Elizabeth R
- Tomita, Yoshihiko
- Mizuno, Ryuichi
- Bedke, Jens
- Zhang, Joshua
- Maurer, Matthew A
- Simsek, Burcin
- Ejzykowicz, Flavia
- Schwab, Gisela M
- Apolo, Andrea B
- Motzer, Robert J
- Titel
- Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- Ist Teil von
- The New England journal of medicine, 2021-03, Vol.384 (9), p.829-841
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2021
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- In a randomized trial involving patients with previously untreated advanced renal-cell carcinoma, nivolumab plus cabozantinib had significant benefits over sunitinib with respect to progression-free and overall survival and the likelihood of response. A total of 19.7% of the patients in the combination group discontinued one or both of the trial drugs prematurely.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793, 1533-4406eISSN: 1533-4406DOI: 10.1056/NEJMoa2026982Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8436591
- Format
- –
- Schlagworte
- Adult, Adverse events, Aged, Aged, 80 and over, Anilides - administration & dosage, Anilides - adverse effects, Antineoplastic Agents - adverse effects, Antineoplastic Agents - therapeutic use, Antineoplastic Combined Chemotherapy Protocols - adverse effects, Antineoplastic Combined Chemotherapy Protocols - therapeutic use, B7-H1 Antigen - antagonists & inhibitors, Cancer therapies, Carcinoma, Renal Cell - drug therapy, Carcinoma, Renal Cell - mortality, Committees, Drug dosages, Female, Humans, Immunotherapy, Inhibitor drugs, Intention to Treat Analysis, Kidney cancer, Kidney Neoplasms - drug therapy, Kidney Neoplasms - mortality, Kinases, Male, Metastasis, Middle Aged, Monoclonal antibodies, Nivolumab - administration & dosage, Nivolumab - adverse effects, Progression-Free Survival, Proportional Hazards Models, Pyridines - administration & dosage, Pyridines - adverse effects, Quality of Life, Receptor Protein-Tyrosine Kinases - antagonists & inhibitors, Renal cell carcinoma, Signal transduction, Statistical analysis, Sunitinib - adverse effects, Sunitinib - therapeutic use, Survival Analysis, Targeted cancer therapy, Vascular endothelial growth factor